Literature DB >> 10473020

Management of onychomycoses.

M Niewerth1, H C Korting.   

Abstract

Onychomycoses, infections of the nail caused by fungi, are amongst the most common illnesses. Because of the high incidence of these infections and problems involved in their therapy, they have received much attention, particularly as concerns a better characterisation of the causative micro-organisms. Onychomycosis caused by dermatophytes (tinea unguium) is most common and is found more frequently on the feet than on the hands. The clinical presentation of onychomycosis is at best indicative of fungal infection, and the growth of a credible pathogen is an indispensable prerequisite for definite diagnosis. The clinical appearance is variable. Four major types of manifestation have been characterised, depending on localisation and spread. New antifungal agents for systemic or topical application based on novel active substances or vehicles are available, and cure is feasible for the majority of cases. Therapy can and should be individualised, depending on the characteristics of the particular case. Currently, continuous or intermittent oral treatment with itraconazole or terbinafine exhibit a particularly favourable risk : benefit ratio. Fluconazole might become an alternative in the near future. With respect to topical treatment, ciclopirox or amorolfine lacquer and the bifonazole/urea combination deserve particular interest. However, cure cannot be expected for every case.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10473020     DOI: 10.2165/00003495-199958020-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  109 in total

1.  Persistent impairment of taste resulting from terbinafine.

Authors:  J L Bong; T W Lucke; C D Evans
Journal:  Br J Dermatol       Date:  1998-10       Impact factor: 9.302

2.  Partial surgical avulsion of the nail in onychomycosis.

Authors:  R Baran; R J Hay
Journal:  Clin Exp Dermatol       Date:  1985-09       Impact factor: 3.470

3.  The in vitro activity of fluconazole against fungi involved in dermal infections.

Authors:  A Wildfeuer; H P Seidl
Journal:  Mycoses       Date:  1994 Nov-Dec       Impact factor: 4.377

4.  Candida nail bed infection and cosmetic acrylic nail extensions--a potential source of hospital infection?

Authors:  J M Symonds; C A O'Dell
Journal:  J Hosp Infect       Date:  1993-03       Impact factor: 3.926

Review 5.  Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview.

Authors:  P D Doncker; A K Gupta; G Marynissen; P Stoffels; A Heremans
Journal:  J Am Acad Dermatol       Date:  1997-12       Impact factor: 11.527

6.  Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis.

Authors:  A K Gupta
Journal:  Pharmacoeconomics       Date:  1998-02       Impact factor: 4.981

Review 7.  Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

8.  Terbinafine in onychomycosis of the toenail: a novel treatment protocol.

Authors:  A Watson; J Marley; D Ellis; T Williams
Journal:  J Am Acad Dermatol       Date:  1995-11       Impact factor: 11.527

9.  Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly.

Authors:  D Reinel; C Clarke
Journal:  Clin Exp Dermatol       Date:  1992-09       Impact factor: 3.470

10.  Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. LAGOS III Study Group.

Authors:  E Haneke; I Tausch; M Bräutigam; G Weidinger; D Welzel
Journal:  J Am Acad Dermatol       Date:  1995-01       Impact factor: 11.527

View more
  10 in total

1.  The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.

Authors:  Keita Sugiura; Noriaki Sugimoto; Shinya Hosaka; Maria Katafuchi-Nagashima; Yoshio Arakawa; Yoshiyuki Tatsumi; William Jo Siu; Radhakrishnan Pillai
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

Review 2.  Pharmacokinetics of antifungal agents in onychomycoses.

Authors:  D Debruyne; A Coquerel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Which antifungal agent for onychomycosis? A pharmacoeconomic analysis.

Authors:  V N Joish; E P Armstrong
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

4.  Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine.

Authors:  Yoshiyuki Tatsumi; Mamoru Yokoo; Hisato Senda; Kazuaki Kakehi
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

Review 5.  Onychomycosis: health-related quality of life considerations.

Authors:  James W Shaw; Vijay N Joish; Stephen Joel Coons
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

6.  In vitro combination therapy using low dose clotrimazole and photodynamic therapy leads to enhanced killing of the dermatophyte Trichophyton rubrum.

Authors:  C Oliver Morton; Mousawi Chau; Colin Stack
Journal:  BMC Microbiol       Date:  2014-10-15       Impact factor: 3.605

7.  Efficacy Coefficients Determined Using Nail Permeability and Antifungal Activity in Keratin-Containing Media Are Useful for Predicting Clinical Efficacies of Topical Drugs for Onychomycosis.

Authors:  Yoshiki Matsuda; Keita Sugiura; Takashi Hashimoto; Akane Ueda; Yoshihiro Konno; Yoshiyuki Tatsumi
Journal:  PLoS One       Date:  2016-07-21       Impact factor: 3.240

8.  The Role of NADPH Oxidase in the Inhibition of Trichophyton rubrum by 420-nm Intense Pulsed Light.

Authors:  Hao Huang; Weibiao Lv; Ying Chen; Xiufeng Zheng; Yong Hu; Ruihua Wang; Meiling Huang; Hongfeng Tang
Journal:  Front Microbiol       Date:  2018-01-09       Impact factor: 5.640

9.  Fungicidal Activity in the Presence of Keratin as an Important Factor Contributing to In Vivo Efficacy: A Comparison of Efinaconazole, Tavaborole, and Ciclopirox.

Authors:  Haruki Tachibana; Naomichi Kumagai; Yoshiyuki Tatsumi
Journal:  J Fungi (Basel)       Date:  2017-10-19

10.  In Vitro Combination Effect of Topical and Oral Anti-Onychomycosis Drugs on Trichophyton rubrum and Trichophyton interdigitale.

Authors:  Keita Sugiura; Akane Masumoto; Haruki Tachibana; Yoshiyuki Tatsumi
Journal:  J Fungi (Basel)       Date:  2021-03-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.